NCT07714538

Breath Research Narrow Validation for Gastrointestinal Cancer Detection

RecruitingOBSERVATIONAL

Trial Details

Start: 2026-07-26Est. Completion: 2028-02-02

Enrollment target: 1,000 participants

Locations

Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom
Liverpool University Hospitals NHS Foundation Trust, Liverpool, Merseyside, United Kingdom
NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom
Royal Free London NHS Foundation Trust, London, United Kingdom
Imperial College Healthcare NHS Trust, London, United Kingdom

Contact

Jessie S McClymont, Medical Biosciences BScbrave-study@imperial.ac.uk +44 7434937543

Other microbiome trials you might be interested in

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsPhase 2Recruiting

Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)

eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer a…

Los Angeles, United StatesEst. completion Nov 30, 2028

View Trial →

Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid TumorsPhase 1Recruiting

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.